Incyte Announces FDA Approval of Pemazyre (pemigatinib) as the First and Only Targeted Treatment for…
Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment…
Read More...
Read More...
